Meticel (Celecoxib)

Celecoxib works by selectively blocking the cyclooxygenase‑2 (COX‑2) enzyme, which converts arachidonic acid into prostaglandins that drive inflammation, pain, and fever. By inhibiting COX‑2 while sparing COX‑1, celecoxib reduces the production of inflammatory prostaglandins in affected tissues without significantly disrupting the protective prostaglandins that maintain gastric lining integrity.

The appropriate dose of Meticel is determined by the prescribing healthcare professional based on the specific indication, severity of symptoms, patient age, weight, renal and hepatic function, and any concomitant medications. Dosage adjustments may be required for patients with cardiovascular risk factors or organ impairment, and the prescriber will tailor the regimen to achieve optimal therapeutic benefit.

Safety data for celecoxib during pregnancy and lactation are limited. Generally, celecoxib is avoided in the first and third trimesters because of potential risks to the fetus, and it is not recommended while breastfeeding unless the benefits outweigh the risks. Women who are pregnant, planning pregnancy, or nursing should discuss alternative therapies with their physician.

To place an order, submit an enquiry on the Meticel product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Meticel (celecoxib) is a COX‑2 selective NSAID, which means it targets the COX‑2 enzyme responsible for inflammation while sparing COX‑1, the enzyme that protects the stomach lining. In contrast, ibuprofen is a non‑selective NSAID that inhibits both COX‑1 and COX‑2, potentially leading to higher gastrointestinal risk. Celecoxib may be preferred for patients needing NSAID therapy with reduced GI irritation, though cardiovascular risk considerations remain.

Meticel should be stored at room temperature, below 25 °C (77 °F). Keep the tablets in the original blister pack or container, protect them from moisture, excessive heat and direct sunlight. Do not store in bathrooms or near kitchen appliances that generate steam, and keep out of reach of children.

Meticel is taken orally, usually as a whole tablet swallowed with a glass of water. It can be taken with or without food; however, taking it with food may reduce occasional stomach discomfort. Patients should follow the dosing schedule prescribed by their healthcare provider and should not split, crush, or chew the tablets unless specifically instructed.

The most serious risks of Meticel include cardiovascular events such as heart attack or stroke, especially in patients with existing heart disease or risk factors. It can also cause serious gastrointestinal complications like bleeding or ulceration, severe skin reactions (e.g., Stevens‑Johnson syndrome), liver enzyme elevations, and renal impairment. Patients should be monitored closely for any signs of these adverse events.

Meticel should be avoided in individuals with known hypersensitivity to celecoxib or any COX‑2 inhibitors, those with active cardiovascular disease (e.g., recent myocardial infarction, uncontrolled hypertension), severe hepatic or renal impairment, and patients with a history of gastrointestinal bleeding or ulcer disease unless protective measures are in place. Pregnant women in the first and third trimesters and nursing mothers should also refrain from using it unless directed by a physician.